Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Crism TherapeuticsAMMCF 35 Debt-to-EBITDA is 0.00 as of Dec. 2025. GuruFocus rates AMMCF with a GF Score™ of 35/100. The stock has 3 warning signs investors should review. Among 305 Biotechnology companies, Crism Therapeutics ranks worse than 327868.52% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Crism Therapeutics's Debt-to-EBITDA or its related term are showing as below:
AMMCF's Debt-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 1.33 * Ranked among companies with meaningful Debt-to-EBITDA only.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Crism Therapeutics Debt-to-EBITDA Related Terms
Crism Therapeutics Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Crism Therapeutics's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AMMCF vs VRTX, REGN, RVMD: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Crism Therapeutics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Crism Therapeutics Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Crism Therapeutics's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Crism Therapeutics's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Crism Therapeutics (AMMCF) has a Debt-to-EBITDA of 0.00 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Crism Therapeutics. According to the industry distribution chart, Crism Therapeutics ranks #999999 out of 305 companies in the Biotechnology industry.
Is Crism Therapeutics' Debt-to-EBITDA too high?
Crism Therapeutics' current Debt-to-EBITDA is 0.00. Based on the distribution chart, Crism Therapeutics ranks #999999 out of 305 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Crism Therapeutics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Crism Therapeutics' Debt-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Crism Therapeutics ranks #999999 out of 305 companies for Debt-to-EBITDA. This places Crism Therapeutics in the lower half of its industry. The industry median Debt-to-EBITDA is 1.33. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.33, based on 305 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Crism Therapeutics. For the Biotechnology industry, the median Debt-to-EBITDA is 1.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Crism Therapeutics's current Debt-to-EBITDA is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crism Therapeutics stock overvalued right now?
Crism Therapeutics (AMMCF) has a current Debt-to-EBITDA of 0.00. The current Debt-to-EBITDA is 0.00. Crism Therapeutics' overall GF Score™ is 35/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Crism Therapeutics (AMMCF), the current Debt-to-EBITDA is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Crism Therapeutics Corp has developed a drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs. Its product ChemoSeed which is in its clinical trial phase, can be implanted directly into the tumour or the resection margin following the removal of a tumour. The company also provides consultancy and formulation services to its clients assisting them with pharmaceutical formulation and development.
35GF Score
Get the complete analysis for AMMCF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMMCF has been successfully added to your 
